Hematology Advisor
LightNews LightNews
banner
hematologyadvisor.bsky.social
Hematology Advisor
@hematologyadvisor.bsky.social
120 followers 140 following 160 posts
HematologyAdvisor.com is a trusted knowledge base of practical information and resources focused on hematology and critical care medicine.
Posts Replies Media Videos
hematologyadvisor.bsky.social
Vaccination and #cancerScreening uptake improved over time among patients with #CLL who repeatedly completed annual health maintenance questionnaires. Presented at upcoming #ASH25. From @rarediseaseadvisor.bsky.social.

https://bit.ly/4oToytP

#leusm
Repeated Surveys Strengthen Preventive Care Engagement in CLL
Serial participation was associated with improved cumulative vaccine coverage.
bit.ly
November 28, 2025 at 9:10 PM
hematologyadvisor.bsky.social
Among racial and ethnic minority populations, patients with #multipleMyeloma have reduced access to BCMA-targeting CAR T-cell therapies.

https://bit.ly/43N6zgf

#HealthDisparities
CAR-T Availability Necessary for Combatting Health Disparities in MM
Patients with MM who are part of racial and ethnic minority populations have reduced access to BCMA-targeting CAR-T therapies.
bit.ly
November 27, 2025 at 4:12 PM
hematologyadvisor.bsky.social
Topline results were announced from a phase 3 trial evaluating #mitapivat, an oral pyruvate kinase activator, in patients with #sickleCellDisease.

https://bit.ly/4pABm8v
Mixed Results for Mitapivat in Sickle Cell Disease Trial
Topline results from the RISE UP phase 3 trial demonstrated that mitapivat significantly improved hemoglobin response in patients with sickle cell disease.
bit.ly
November 26, 2025 at 5:25 PM
hematologyadvisor.bsky.social
Adding the FLT3 inhibitor quizartinib to standard chemotherapy significantly improved EFS and OS in patients with newly diagnosed FLT-ITD–negative #acuteMyeloidLeukemia. Published in @ascopost.bsky.social.

https://bit.ly/48hcziF

#AML #leusm
Quizartinib Improves Survival in Newly Diagnosed FLT3-ITD–Negative AML
Researchers determined quizartinib plus chemotherapy significantly improved event-free survival and overall survival in patients with newly diagnosed FLT-ITD–negative AML.
bit.ly
November 25, 2025 at 9:18 PM
hematologyadvisor.bsky.social
#AplasticAnemia is a rare blood disease that occurs when the bone marrow stops making enough new blood cells.

https://bit.ly/4ijicl2

#anemia
What Is Aplastic Anemia? Symptoms, Causes, and Procedure
Aplastic anemia is a rare blood disease where the bone marrow stops making enough new blood cells, with symptoms like pale skin and fatigue.
bit.ly
November 24, 2025 at 6:10 PM
hematologyadvisor.bsky.social
#COVID19vaccination, particularly when combined with prior infection, substantially reduces the risk for #longCOVID among #HCWs. Published in @cidjournal.bsky.social and @infectiousdisease.bsky.social.

https://bit.ly/43HuFc5

#COVID19
Hybrid Immunity Significantly Reduces Long COVID Risk in Health Care Workers
COVID-19 vaccination, especially with prior infection, significantly reduced the risk for long COVID in health care workers.
bit.ly
November 23, 2025 at 6:43 PM
hematologyadvisor.bsky.social
Granulomatous acute interstitial nephritis is a rare but important cause of renal dysfunction in patients with chronic #lymphocyticLeukemia. From @rarediseaseadvisor.bsky.social.

https://bit.ly/49u4fym

#CLL #leusm
Granulomatous Acute Interstitial Nephritis Can Cause Renal Dysfunction in CLL
The patient initiated treatment with zanubrutinib and high-dose corticosteroids, resulting in partial improvement in renal function.
bit.ly
November 22, 2025 at 8:49 PM
hematologyadvisor.bsky.social
#Hematologists in the United States report significant disparities in diagnostic and treatment approaches for individuals with mild #hemophilia. Published in @rarediseaseadvisor.bsky.social.

https://bit.ly/48oCp5m
Distinct Care Strategies Are Needed for Mild Hemophilia
Predicting bleeding risk and concerns regarding over- or undertreating were common concerns among clinicians.
bit.ly
November 21, 2025 at 8:54 PM
hematologyadvisor.bsky.social
Ruxolitinib performed better than best available therapy in the management of a cohort of patients with SR-aGVHD over a 24-month period. Published in the @ascopost.bsky.social journal Journal of Clinical Oncology.

https://bit.ly/3XEBLuq

#GVHD
Ruxolitinib Superior to Best Available Therapy in Managing Steroid-Refractory Acute GVHD
Researchers determined ruxolitinib performed better than best available therapy in the management of a cohort of patients with SR-aGVHD over a 24-month period.
bit.ly
November 20, 2025 at 4:08 PM
hematologyadvisor.bsky.social
Diagnostic delays for patients having symptoms of #VTE were associated with increased rates of all-cause mortality. Reported in @jamanetworkopen.com.

https://bit.ly/44cOqZf
Diagnostic Delays Associated With Increased Mortality in VTE
Researchers determined diagnostic delays for patients having symptoms of VTE were associated with increased rates of all-cause mortality.
bit.ly
November 19, 2025 at 10:14 PM
hematologyadvisor.bsky.social
A secret shopper study in which researchers posed as AYAs with acute #lymphoblasticLeukemia trying to schedule an #oncology appointment has found that this population faces significant logistical burdens when accessing initial oncology care. From #ASCO25.

https://bit.ly/4ib5gh0

#leusm #lymsm
Significant Barriers Exist in Accessing Initial Oncology Care Among Young Adults with ALL
Researchers determined AYAs with ALL trying to schedule oncology appointments face logistical burdens when accessing initial oncology care.
bit.ly
November 18, 2025 at 8:26 PM
hematologyadvisor.bsky.social
When treated with ICIs, #cancerpatients with a pre-existing anxiety diagnosis appear to experience more irAEs and have better OS than those without anxiety. Published in @cancertherapyadv.bsky.social.

https://bit.ly/4894cqo
Anxiety Increases irAEs but Boosts OS in Cancer Patients Receiving Immunotherapy
Study researchers noted that the findings suggest the association between anxiety and improved OS was at least partly related to the higher incidence of irAEs, which implies that, in people with an anxiety disorder, immunotherapy “may result in greater ...
bit.ly
November 16, 2025 at 6:17 PM
hematologyadvisor.bsky.social
Researchers developed a new model to aid in individualized decision making around the use of prophylactic platelet transfusion in preterm infants who have severe #thrombocytopenia. Reported in @jama.com.

https://bit.ly/47KN1LX
Predicting Transfusion Outcomes in Preterm Infants With Severe Thrombocytopenia
Researchers developed a model to aid in individualized decision making around the use of prophylactic platelet transfusion in preterm infants who have severe thrombocytopenia.
bit.ly
November 15, 2025 at 8:51 PM
hematologyadvisor.bsky.social
Multiple studies have demonstrated variable incidence rates of #VTE across racial and ethnic groups in the United States.

https://bit.ly/43LvCjR

#HealthDisparities
Addressing Racial and Ethnic Disparities in VTE, DVT Treatment and Outcomes
Studies have indicated there are racial and ethnic disparities in the treatment and outcomes of patients with VTE or DVT.
bit.ly
November 14, 2025 at 9:05 PM
hematologyadvisor.bsky.social
Among patients with transplant-ineligible R/R #LBCL, combining mosunetuzumab with polatuzumab vedotin appears to reduce the risk of disease progression or death compared with R-GemOx. Published in @ascopost.bsky.social Journal of Clinical Oncology.

https://bit.ly/3WQSyKr

#lymphoma #lymsm
Mosunetuzumab Plus Polatuzumab Vedotin Yields High CR Rate in Relapsed, Refractory LBCL
Researchers determined combining mosunetuzumab with polatuzumab vedotin appears to reduce the risk of disease progression or death compared with R-GemOx in LBCL.
bit.ly
November 13, 2025 at 3:46 PM
hematologyadvisor.bsky.social
In patients with severe #aplasticAnemia, upfront allogeneic HCT using alternative donors has become an option for some, but this method has had limited utilization. From @bloodjournals.hematology.org.

https://bit.ly/48bV1FK

#anemia
Use of Alternative Donor HCT Limited in Patients With Severe Aplastic Anemia
In patients with SAA, upfront allogeneic HCT using alternative donors has become an option for some, but this method has had limited utilization.
bit.ly
November 12, 2025 at 4:30 PM
hematologyadvisor.bsky.social
Betty Pace, MD, of Augusta University talks about research to look forward to at the @ash.hematology.org meeting #ASH25.

https://bit.ly/4p3Sjry

#PedHeme #PedOnc
Video: What to Look Forward to at the 2025 ASH Annual Meeting With Betty Pace, MD
Betty Pace, MD, of August University talks about research to look forward to at the American Society of Hematology (ASH) 2025 meeting.
bit.ly
November 11, 2025 at 8:11 PM
hematologyadvisor.bsky.social
@ash.hematology.org President Belinda R. Avalos, MD, shares her perspectives on the past year’s political changes and how they are affecting #hematology research and care.

https://bit.ly/474ugkS

#HemOnc
ASH Works to Support Hematologists, Patients Through Uncertain Political Period
ASH President Belinda R. Avalos, MD, shares perspective on recent political changes and how ASH is supporting hematologists' research.
bit.ly
November 11, 2025 at 8:11 PM
hematologyadvisor.bsky.social
Pretreatment blood signatures in patients with #DLBCL may indicate the likelihood of successful CAR T-cell therapy outcomes and could guide pretherapeutic approaches. Presented at #ESMO25.

https://bit.ly/3Ll4MIU

#lymsm #lymphoma
Pretreatment Immune Composition Influences CAR-T Efficacy in DLBCL
All patients with detectable circulating B cells prior to treatment achieved complete remission.
bit.ly
November 10, 2025 at 6:13 PM
hematologyadvisor.bsky.social
Unlike traditional #Medicare patients, Medicare Advantage enrollees who need major gen/gastro cancer surgery frequently use lower quality hospitals rather than high-quality teaching hospitals. @jamasurgery.com @renalurologynews.bsky.social.

https://bit.ly/4hLzJSA

#gicsm #GCAM
Cancer Surgery at High-Quality Hospitals Less Likely for Medicare Advantage Patients
A US study investigated whether Medicare Advantage plans limit access to high-quality cancer surgery.
bit.ly
November 9, 2025 at 6:39 PM
hematologyadvisor.bsky.social
Once-weekly subcutaneous marstacimab significantly reduced bleeding rates and was well tolerated in male patients with severe #hemophilia A or moderately severe to severe hemophilia B without inhibitors. Published in @bloodjournals.hematology.org.

https://bit.ly/47osaO7
Once-Weekly Marstacimab Reduces Bleeding Rates and Is Well Tolerated in Severe Hemophilia A and B
Marstacimab significantly reduced bleeding rates and was well tolerated in males with severe hemophilia A or moderately severe to severe hemophilia B without inhibitors.
bit.ly
November 8, 2025 at 7:14 PM
hematologyadvisor.bsky.social
In older cancer patients, receiving federal housing assistance is associated with earlier-stage diagnosis of #breastcancer, #colorectalcancer, and #NSCLC. Published in @jamanetworkopen.com and @cancertherapyadv.bsky.social.

https://bit.ly/4oVG9RB

#bcsm
In Older Adults, Federal Housing Assistance Is Linked to Stage of Cancer Diagnosis
In older cancer patients, receiving federal housing assistance is associated with earlier-stage diagnosis of breast cancer, colorectal cancer, and NSCLC.
bit.ly
November 7, 2025 at 7:13 PM
hematologyadvisor.bsky.social
Ultra-low-pass whole genome sequencing of circulating tumor DNA appears to provide important prognostic information regarding patients with #LBCL. Published in @ascopost.bsky.social JCO Precision Oncology and @hematologyadvisor.bsky.social.

https://bit.ly/4nzwSO1

#lymsm #lymphoma
Whole Genome Sequencing Shows High Prognostic Utility in LBCL - Oncology Nurse Advisor
Researchers assessed whether ULP-WGS would have prognostic utility in patients with LBCL.
bit.ly
November 7, 2025 at 7:13 PM
hematologyadvisor.bsky.social
#Oncologist coverage across the US has declined in recent years, leading to #caregaps. Published in @ascopost.bsky.social JCO Oncology Practice and @cancertherapyadv.bsky.social.

https://bit.ly/43dRtjt
Oncologist Care Gaps Affect Rural, Disadvantaged Populations Most
The care gaps are more pronounced among rural populations, and in counties with a higher levels of cancer mortality, health risks, and socioeconomic risks, researchers reported.
bit.ly
November 6, 2025 at 4:12 PM
hematologyadvisor.bsky.social
Once-weekly subcutaneous marstacimab significantly reduced bleeding rates and was well tolerated in male patients with severe #hemophilia A or moderately severe to severe hemophilia B without inhibitors. Published in @bloodjournals.hematology.org.

https://bit.ly/47osaO7
Once-Weekly Marstacimab Reduces Bleeding Rates and Is Well Tolerated in Severe Hemophilia A and B
Marstacimab significantly reduced bleeding rates and was well tolerated in males with severe hemophilia A or moderately severe to severe hemophilia B without inhibitors.
bit.ly
November 5, 2025 at 7:35 PM